NCT05978739 - Evaluating Different Doses of Orelabrutinib in MCL | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 18, 2023

Primary Completion Date

February 25, 2025

Study Completion Date

May 25, 2025

Conditions

Mantle Cell Lymphoma

Interventions

DRUG

Orelabrutinib High dose

Orelabrutinib will be administered as 3 tablets once per day

DRUG

Orelabrutinib Low dose

Orelabrutinib will be administered as 1 tablet once per day

Trial Locations (20)

100191

NOT_YET_RECRUITING

Peking University Third Hospital, Beijing

110001

RECRUITING

The First Affiliated Hospital of China Medical University, Shenyang

116023

RECRUITING

The Second Hospital of Dalian Medical University, Dalian

230022

NOT_YET_RECRUITING

The First Affiliated Hospital of Anhui Medical University, Hefei

233040

RECRUITING

The First Affiliated Hospital of Bengbu Medical College, Bengbu

310003

NOT_YET_RECRUITING

The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou

330006

RECRUITING

The Second Affiliated Hospital of Nanchang University, Nanchang

330029

RECRUITING

Jiangxi Cancer Hospital, Nanchang

400030

RECRUITING

Chongqing Cancer Hospital, Chongqing

410031

RECRUITING

Hunan Cancer Hospital, Changsha

423003

RECRUITING

Chenzhou First People's Hospital, Chenzhou

430022

RECRUITING

Union Hospital Tongji Medical College, Huazhong University of Science and Technology, Wuhan

430079

RECRUITING

Hubei Cancer Hospital, Wuhan

450003

RECRUITING

Henan Cancer Hospital, Zhengzhou

450052

RECRUITING

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

473009

NOT_YET_RECRUITING

Nanyang Second General Hospital, Nanyang

510055

RECRUITING

Sun Yat-sen University Cancer Center, Guangdong

710004

NOT_YET_RECRUITING

The Second Affiliated Hospital of Xi'an Jiaotong University, Xi’an

830000

RECRUITING

The Affiliated Cancer Hospital of Xinjiang Medical University, Ürümqi

030013

NOT_YET_RECRUITING

Shanxi Provincial Cancer Hospital, Taiyuan